Immunotherapy Combinations in Multiple Myeloma - Known Unknowns

The FDA required labeling changes for the programmed cell death 1 inhibitor pembrolizumab and thalidomide-analogue immunomodulatory agents to include information on increased mortality in multiple myeloma. Yet PD-1 therapy's role in the disease is not a closed book.